TRULICITY Solution for Injection
Dulaglutide
0.75 mg, 1.5 mg
ALMIRALL HERMAL GmbH
| Pack size | 4 Pre-filled pen (0.5 ml) |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 90.60 AED |
Indications
TRULICITY Solution for Injection is used for:
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Dulaglutide :
Mechanism of Action
Dulaglutide is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.
Note
TRULICITY 0.75 mg, 1.5 mg Solution for Injection manufactured by ALMIRALL HERMAL GmbH. Its generic name is Dulaglutide. TRULICITY is availble in Saudi Arabia.
Farmaco SA drug index information on TRULICITY Solution for Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.